At a glance
- Originator NPS Pharmaceuticals
- Class Alkanes; Neuroprotectants; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 22 Nov 2000 Discontinued-Preclinical for Neurological disorders (Prevention) in USA (Unknown route)
- 06 Jan 2000 New profile
- 06 Jan 2000 Preclinical development for Neurological disorders (Prevention) in USA (Unknown route)